Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

Incidence rates of Merkel cell carcinoma (MCC), an uncommon skin cancer with an aggressive disease course, have increased in recent decades. Limited treatment options are available for patients with metastatic MCC (mMCC). Avelumab, an anti‐programmed cell death‐ligand 1 monoclonal antibody, became t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo Antonio, Orlova, Kristina, Grignani, Giovanni, Dudzisz‐Śledź, Monika, Fenig, Eyal, Chiarion Sileni, Vanna, Fazio, Nicola, Samimi, Mahtab, Mortier, Laurent, Gebhardt, Christoffer, Kramkimel, Nora, Steven, Neil, Bechter, Oliver, Arance, Ana, Benincasa, Elena, Kostkova, Lenka, Costa, Nuno, Lorigan, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291083/
https://www.ncbi.nlm.nih.gov/pubmed/34310716
http://dx.doi.org/10.1002/ijc.33746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291083/
https://www.ncbi.nlm.nih.gov/pubmed/34310716
http://dx.doi.org/10.1002/ijc.33746

Ejemplares similares